echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In the second quarter of 2020, the market capitalization of multinational pharmaceutical companies ranked in the top five unchanged

    In the second quarter of 2020, the market capitalization of multinational pharmaceutical companies ranked in the top five unchanged

    • Last Update: 2020-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    GlobalData, a data analytics and consulting firm, recently released market capitalization rankings and changes in the top 20 innovative pharmaceutical companies in the second quarter of 2020.
    market capitalisation of the world's top 20 pharmaceutical companies rose 10.2 per cent to about $2.8 trillion in the second quarter, a marked rebound from the first quarter.
    the top five companies in the U.S. market capitalisation remained unchanged from the first quarter, followed by Johnson and Johnson, Roche, Novar3, Merck and Pfizer.
    , Johnson and Johnson's market capitalisation grew 7.2 per cent month-on-month in the second quarter, remaining at the top of the list.
    company reported global revenue of $18.336 billion, down 10.8 percent from a year earlier, and net profit of $3.626 billion, down 35.3 percent from a year earlier, according to the company's 2020 Q2 results.
    all of Johnson and Johnson's businesses, only the pharmaceutical business, Janssen, grew 2.1 per cent year-on-year, excluding acquisitions and divestitures, up 3.9 per cent year-on-year.
    the reasons for the growth of the pharmaceutical business, in addition to cardiovascular/metabolic products, mainly from the immunology sector products, infectious disease products, neuroscience products, pulse artery high pressure products five products.
    's market capitalisation rose 5.3 per cent month-on-month in the second quarter.
    first half of the year, Roche's sales and profits both fell.
    sales for the current period were 29.281 billion Swiss francs (about $32.2 billion), compared with 30.469 billion Swiss francs a year earlier.
    , pharmaceutical sales were SFr23.2bn, down 4 per cent year-on-year.
    s diagnostics business has sales of CHF 6.1 billion.
    first-half net profit also fell 5 per cent to 8.5bn Swiss francs, down from 8.9bn Swiss francs a year earlier.
    's market capitalisation rose 1.15 per cent month-on-month in the second quarter.
    net sales of $11.347 billion in the second quarter, compared with $11.764 billion a year earlier.
    profit for the quarter was $2,352 million, compared with $2,663 million a year earlier.
    net profit for the quarter was $1,867 million, compared with $2.109 billion a year earlier.
    , net sales of innovative drugs were $9,188 million and net sales of Sands were $2,159 million.
    said it was mainly public health events that were dragging down the ophthalmology and dermatology business.
    's market capitalisation remained flat in the second quarter.
    net sales for the quarter were EUR 4,119 million, compared with EUR 3,971 million a year earlier.
    profit for the quarter was EUR 1,048 million, compared with EUR 1,074 million a year earlier.
    , the life sciences business had net sales of EUR 1.806 billion (approximately US$2.13 billion), the health care business had net sales of EUR 1,499 million (approximately US$1.77 billion) and the materials business had net sales of EUR 814 million.
    Pfizer rose 0.3 percent month-on-month.
    Pfizer's second quarter 2020 results.
    revenue for the quarter was $11.8 billion, down 11 percent from $13.264 billion a year earlier.
    , the biopharmaceutical business generated $9.8 billion in revenue and The Strong business generated $2 billion in revenue.
    net profit for the quarter was $3.426 billion, down 32 percent from $5,046 million a year earlier.
    half of the companies on the list grew by more than 10 per cent, with AbbVie's second-quarter market capitalisation up 53.8 per cent month-on-month.
    revenue for the quarter was $10,425 million, up 26.3 percent from $8,255 million a year earlier.
    net loss for the quarter was $738 million, compared with a net profit of $741 million a year earlier.
    moved up to sixth place, thanks largely to the completion of allergan's acquisition and expansion of the product pipeline.
    's pharmaceutical companies, which grew by more than 20 percent in market value in the second quarter, included Bayer and Vertex, with Bayer posting a net loss of 9,548 million euros for the quarter, compared with a net profit of 404 million euros a year earlier, after accounting for huge one-time expenses related to the settlement of a U.S. herbicide cancer lawsuit.
    , crop science sales were 4.8 billion euros, pharmaceutical sales 4 billion euros ($4.72 billion) and consumer health sales 1.2 billion euros.
    Vertex continued its upward trend in the second quarter due to its dominant position in cystic fibrosis (CF) therapy.
    addition, The 13th and Takeda Pharmaceuticals are new to the top 20 companies, with market capitalization growth of 18.7% and 16.6% respectively in the second quarter.
    the former because potential cancer drug candidates and clinical trial collaborations helped drive market capitalization growth in the second quarter.
    the latter was strong due to strong sales growth in the rare disease drug Takhzyro and the anti-tumor drug Ninlaro.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.